FDA Publishes Final Guidance on Medical Device Reporting
Today FDA released its final guidance, “Medical Device Reporting for Manufacturers”. The goal of the document is to help manufacturers meet applicable reporting and recordkeeping requirements for specific adverse events and product malfunctions. The guidance supersedes the 2013 draft guidance, as well as the 1997 manufacturer MDR guidance document.
There have been numerous changes to the medical device reporting requirements since the FD&C Act first described them and the Medical Device Reporting regulation became effective over 20 years ago. The FDA’s final guidance on medical device reporting for manufacturers updates its policy and clarifies the agency’s interpretations of the regulatory requirements under 21 CFR part 803. – FDA release
FDA has also scheduled a webinar to help companies understand the final guidance and answer questions. The event takes place on Wednesday, November 30, 1–2:30 pm ET . The presentation slides will also be available the morning of the webinar.
Related Articles
-
The guidance is intended to clarify the FDA’s approach for referencing the terms “device” and “counterfeit device” in FDA documents, as well as how the agency intends to interpret existing references to section 201(h) of the FD&C Act in guidance,…
-
The new guidance is intended to establish confidence in automation used for production or quality assurance systems and describe various methods and testing activities that may be applied to establish computer software assurance and meet regulatory software validation requirements.
-
The MDDT program was developed in collaboration with the National Institutes of Health’s (NIH’s) National Institute of Drug Abuse (NIDA), National Institute of Dental Craniofacial Research (NIDCR) and National Cancer Institute (NCI) as a way for the FDA to qualify…
-
The FDA does not intend to enforce the GUDID submission requirements for Class I and unclassified devices, other than implantable, life-supporting or life-sustaining devices, regardless of whether they are consumer health products, before December 8, 2022.
